These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2474572)

  • 1. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.
    Seifert PS; Hansson GK
    J Clin Invest; 1989 Aug; 84(2):597-604. PubMed ID: 2474572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall.
    Niculescu F; Rus HG; Vlaicu R
    Immunol Lett; 1990 Oct; 26(1):17-23. PubMed ID: 1703512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.
    Shibata T; Cosio FG; Birmingham DJ
    J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
    Horta MF; Ramalho-Pinto FJ
    J Exp Med; 1991 Dec; 174(6):1399-406. PubMed ID: 1720809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis.
    Mason JC; Lidington EA; Yarwood H; Lublin DM; Haskard DO
    Arthritis Rheum; 2001 Jan; 44(1):138-50. PubMed ID: 11212152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland.
    Lass JH; Walter EI; Burris TE; Grossniklaus HE; Roat MI; Skelnik DL; Needham L; Singer M; Medof ME
    Invest Ophthalmol Vis Sci; 1990 Jun; 31(6):1136-48. PubMed ID: 1693916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement.
    Venneker GT; Vodegel RM; Okada N; Westerhof W; Bos JD; Asghar SS
    Immunobiology; 1998 Feb; 198(4):476-84. PubMed ID: 9562871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
    Fujita T; Shinkai Y; Inoue T; Tamura N
    Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement receptors and regulatory proteins in human atherosclerotic lesions.
    Seifert PS; Hansson GK
    Arteriosclerosis; 1989; 9(6):802-11. PubMed ID: 2480105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.
    Simpson KL; Jones A; Norman S; Holmes CH
    Am J Pathol; 1997 Nov; 151(5):1455-67. PubMed ID: 9358772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes.
    Bao L; Spiller OB; St John PL; Haas M; Hack BK; Ren G; Cunningham PN; Doshi M; Abrahamson DR; Morgan BP; Quigg RJ
    Kidney Int; 2002 Dec; 62(6):2010-21. PubMed ID: 12427125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
    Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
    Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Kinoshita T; Rosenfeld SI; Nussenzweig V
    J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.